hosted by
publicationslist.org

Knut M Wittkowski

knut@asdera.com

All Tags: *, *AIDS Serodiagnosis, *Artificial Intelligence (2), *Attention, *Bone Marrow Transplantation/mortality, *Cell Movement/drug effects, *Computational Biology, *Computer Graphics, *Condoms (2), *Contraception, *Data Interpretation, *Database Management Systems, *Discrimination Learning, *EP/PC/TM, *Epidemiologic Methods, *Gene Expression Profiling (2), *Genetic Predisposition to Disease, *Health Knowledge, *Health Status Indicators, *HIV Infections, *Immunologic Memory/drug effects, *Joints, *Linkage Disequilibrium, *Mathematical Computing, *Models, *Multivariate Analysis, *Nails, *Nonoxynol, *Oligonucleotide Array Sequence Analysis, *Pain, *Patient Compliance, *Polymerase Chain Reaction, *Polymorphism, *Postoperative Complications, *Reproductive Techniques, *Research Design (2), *Reward, *Risk Factors, *Risk-Taking, *Serial Learning, *Sexual Behavior (2), *Skin, *Software, *Spermatocidal Agents, *TD, *Time Perception, *User-Computer Interface, 1.3% and 2.5%., 50 contacts/year, 80 and over, 99% compliance givers .3% and 1.5% risk/contact for 100 and for, aCD, Acquired Immunodeficiency Syndrome/*complications/diagnosis, Acquired Immunodeficiency Syndrome/*prevention & control, activation, Acute Disease, Acute-Phase Proteins/metabolism, Adjuvants (3), Administration (2), Adolescent (8), Adoptive/methods (2), Adult (14), Aged (5), AIDS Serodiagnosis, Alanine Transaminase/blood, Alfentanil, Algorithms (2), Alleles, AMERICAN-HEART-ASSOCIATION, an infection, Analgesics/therapeutic use, analysis, and for 100% compliance, and reasonable assumptions about the underlying statistics of, and whose relationship has survived a 3-6 month test, Anesthesia (2), Animal (2), Animals (5), Anti-Infective Agents/*therapeutic use, Antibodies (4), Antibody Formation/drug effects/immunology, Antibody Specificity/drug effects/immunology, Antigens (16), Antiviral Agents/*adverse effects/therapeutic use, Antiviral Agents/*therapeutic use, Apolipoproteins E/*deficiency/*genetics, are effective countermeasures against human immunodeficiency virus (HIV), ARTERIAL STIFFNESS, Arteriosclerosis/*genetics, Arthritis, Artifacts (2), Assisted, Atherosclerosis/diagnosis/*epidemiology, ATTITUDE, Attitudes (2), autism, Autoimmune Diseases/drug therapy/*genetics/immunology, Automation, Bee Venoms/chemistry/isolation & purification/pharmacology, Bee Venoms/enzymology/*immunology, Bees/*immunology, Bees/immunology, Behavior, BEHAVIOR, Binomial Distribution, Biological Markers/metabolism, Biology, Biomedical Engineering, Biometry/*methods, Biostatistics/*methods, Birth Weight, Blood Platelets/*metabolism, Brain/*drug effects/metabolism, Breast Neoplasms/*etiology, BRIDGE, but unless compliance is nearly perfect the barrier, C-REACTIVE PROTEIN, Cancer Vaccines/*immunology, Cancer Vaccines/*immunology/therapeutic use, Cancer Vaccines/administration & dosage/immunology/*therapeutic use, Cancer Vaccines/adverse effects/*immunology/*therapeutic use, Carcinoma, Cardiovascular Diseases/*blood/prevention & control, Cardiovascular Diseases/genetics, CARDIOVASCULAR-DISEASE, Carotid Arteries/pathology (2), Case-Control Studies, Cause of Death, CD/analysis, CD/biosynthesis, CD/immunology, CD11/*drug effects/immunology/metabolism, CD11c/biosynthesis, CD18/immunology/metabolism, CD2/*immunology, CD3/analysis, CD34/*analysis, CD34/*immunology (2), CD4-Positive T-Lymphocytes/immunology, CD40/biosynthesis, CD8-Positive T-Lymphocytes/*immunology, CD8-Positive T-Lymphocytes/immunology, CD86/biosynthesis, Cell Separation (2), cell-activation, cells, censoring, Centrifugation, Cesarean Section/statistics & numerical data, Child (5), Chromosome Mapping/*methods, Chronic/*complications/*drug therapy/virology, Clinical Trials (2), Clinical Trials as Topic, Clinical Trials as Topic/*methods, Clinical Trials as Topic/statistics & numerical data, Cluster Analysis, Combined Modality Therapy, Communicable Diseases/*blood/*diagnosis/genetics, Computational Biology/*methods, Computational Biology/methods, computational biostatistics, Computer-Assisted (3), condom plus, Condoms/statistics & numerical data, Confounding Factors (Epidemiology), Contraceptive Devices, Contrast Media, CORONARY-ARTERY, Cross-Sectional Studies, Crosses, Cyclosporine/*administration & dosage, CYSTATIN-C, Cytokines/blood, Cytokines/genetics/immunology, Cytomegalovirus Infections/drug therapy/*prevention & control/virology, Cytomegalovirus/genetics/immunology, Cytotoxic/*immunology, Cytotoxicity (2), Data Collection/statistics & numerical data, Data Interpretation (3), Databases (2), Delayed/immunology, Dendritic Cells/*cytology/metabolism, Dendritic Cells/*drug effects/immunology, Dendritic Cells/*immunology (4), Density Gradient/methods, depends upon the credibility of the partner. A large part of the, Dermatologic Agents/administration & dosage/therapeutic use, Diet, diet, Dietary Fats/*administration & dosage, Dietary Fats/administration & dosage/*adverse effects, Dietary Supplements, Differentiation, Dinoprostone/immunology, Disease, Disease Models, Disease Progression (2), DNA (2), DNA Primers, DNA Virus Infections/*complications/virology, DNA Viruses/genetics/isolation & purification, Docosahexaenoic Acids/*pharmacology/therapeutic use, Dopamine D2/genetics, Dopamine D3, dosage/pharmacokinetics/pharmacology, dosage/pharmacology/*therapeutic use, Dose-Response Relationship (2), Double-Blind Method, Down-Regulation, Down-Regulation/drug effects/genetics, Drug, DYSFUNCTION, Eating Disorders/genetics/metabolism, Educational Status, effectiveness scarcely plays a role., ENDOTHELIAL, Endpoint Determination/*statistics & numerical data, Enflurane/administration & dosage/adverse effects, Enkephalins/genetics, Enzyme-Linked Immunosorbent Assay, Epidemiologic Methods, epilepsy, Epilepsy/ genetics, Epistasis, Escherichia coli Infections/classification/genetics/microbiology, Evaluation Studies as Topic (2), exact test, example, Expert Systems, expression, Factor, Factual, Family Planning Services, Feasibility Studies, Female (25), Fentanyl/administration & dosage/analogs & derivatives, fertility, Flow Cytometry, Fluorescence, Follow-Up Studies, for, for example, Ganciclovir/adverse effects/therapeutic use, Gene Expression Profiling (2), Gene Expression Profiling/*methods, Gene Expression Profiling/statistics & numerical data, Gene Expression Regulation, Gene Expression/*drug effects/genetics, Gene Expression/drug effects, Genetic (3), Genetic Predisposition to Disease/*genetics, Genetic/genetics, genetics (2), genome-wide association studies, Genome-Wide Association Study/ statistics & numerical data, genome-wide significance, Genomics/*methods, Genotype, Germany/epidemiology (3), Gonorrhea/prevention & control, Guidelines as Topic, HABIT, Halothane/adverse effects, Headache/*chemically induced, Headache|*CI, Health, Health Knowledge, HEALTH-PROFESSIONALS, Helper-Inducer/*drug effects/immunology, Hematopoietic Stem Cells/*immunology, Hemocyanin/immunology, Hepatitis B Surface Antigens/analysis, Hepatitis B/*complications/diagnosis, Hepatitis C, Hepatocellular/*blood supply/complications/*radiography, Herpes Genitalis/prevention & control, Heterozygote, HIV Antibodies/analysis, HIV Infections (2), HIV Infections/*epidemiology, HIV Infections/*epidemiology/prevention & control/transmission, HIV Infections/*prevention & control (2), HIV Infections/*prevention & control/*transmission, HIV Infections/*prevention & control/transmission, HIV Infections/mortality/prevention & control/*transmission, HIV Infections/prevention & control/transmission, HIV Seropositivity/*complications, HIV Seroprevalence, HIV Seroprevalence/*trends, HLA-A2 Antigen/immunology (2), HLA-DR Antigens/*genetics, HLA-DR Antigens/metabolism, however, HPaCD, Humans (41), Hyaluronic Acid/*immunology, Hyaluronoglucosaminidase/*immunology, Hypersensitivity, Hypersensitivity/*immunology, Image Processing (2), immune, Immunoglobulin E/blood/immunology, Immunoglobulin E/drug effects/immunology, Immunoglobulin G/blood/immunology, Immunoglobulin G/drug effects/immunology, Immunoglobulins/analysis, Immunoglobulins/biosynthesis, Immunohistochemistry, Immunologic (4), Immunologic/pharmacology, Immunologic/therapeutic use, Immunosuppressive Agents/*administration & dosage, Immunotherapy (2), Inbred AKR, Inbred BALB C (3), Inbred C3H (2), Inbred C57BL (2), Inbred DBA, Inbred Strains, Incidence (2), Infant (4), infection. The experience of several thousand years, Inflammation, Inflammation Mediators/blood, Inflammation Mediators/chemistry/*immunology/isolation & purification, Inhalation/*adverse effects, Inhalation|*AE, Injections, Interferon Alfa-2b/*therapeutic use, Interleukin-10/blood, Interleukin-17/genetics, Interleukin-2 Receptor alpha Subunit/analysis, into an HIV risk per contact. For a Pearl index = 5, Intralesional, Intravaginal (2), Isoflurane/adverse effects, keratinocyte, Knockout, Langerhans Cells/immunology, Leukocytes/*metabolism, Likelihood Functions (3), Linear Models, lipids, Lipids/blood, Lipoproteins/*blood, Liver Cirrhosis/complications/*radiography, Liver Diseases/complications/virology, LONG-TERM MANAGEMENT, Lupus Erythematosus, Lymphocyte Activation, Lymphocyte Activation/drug effects/immunology, Lymphocyte Count (2), Lymphocyte Subsets/drug effects/pathology, Lysosome-Associated Membrane Glycoproteins/metabolism, Magnetic Resonance Spectroscopy, Male (23), marginal likelihood, Mass Spectrometry, Mathematical Computing, Mefenamic acid, Melanoma/*immunology/*therapy (2), Melanoma/*immunology/therapy, Melanoma/immunology/secondary/*therapy, Membrane Glycoproteins/analysis, Membrane Glycoproteins/biosynthesis, Messenger/chemistry/genetics, Messenger/drug effects/metabolism, Messenger/metabolism, Metabolic Networks and Pathways/ genetics, Mice (15), Microarray Analysis/standards/*statistics & numerical data, Microbubbles, Microscopy, Middle Aged (8), minor allele frequency, MO/PC/*TM, MOBILITY, MODE CHOICES, Models (5), Molecular Weight, molecules, Monoclonal/*administration &, Monoclonal/*pharmacology, Monophenol Monooxygenase/metabolism, Morphine/*pharmacology, Mucocutaneous Lymph Node Syndrome/complications/*metabolism/*pathology, Multidimensional data, Multiple Sclerosis/*genetics, Multivariate Analysis (3), Nausea/*chemically induced, Nausea|*CI, Neoplasm Staging, Neoplasm/*immunology, Neoplasm/immunology, Neovascularization, Neural Pathways/drug effects/*metabolism, Neutropenia/chemically induced, Newborn (3), Nitric Oxide Synthase Type II/genetics, Nitric Oxide Synthase Type II/metabolism/*physiology, nonoxynol-9, Nonoxynol/*therapeutic use, Nonoxynol/adverse effects/*therapeutic use, Nonparametric (3), NONPARAMETRIC STATISTICS, North Carolina/epidemiology, Nucleus Accumbens/drug effects/metabolism, nutrition, Obesity/*blood/drug therapy, of infection and thus no need for HIV prophylaxis. The success of this, oligonucleotide array, Oligonucleotide Array Sequence Analysis, Oligonucleotide Array Sequence Analysis/*instrumentation/*methods, Oligonucleotide Array Sequence Analysis/*methods, Oligonucleotide Probes/chemistry, Oligonucleotides/chemistry, Opioid Peptides/genetics, Ordinal variables, Pain, Particle Size, partner from a population with low HIV prevalence is also weak because it, Pathologic/*radiography, Patient Compliance, Pearl index pertaining to a given barrier method, Peptides/drug effects/immunology/isolation & purification, Pharmacogenetics, Phase II as Topic, Phase III as Topic, Phenotype (2), Phospholipases A/chemistry/isolation & purification/pharmacology, Phospholipases A1, Plant Extracts/*pharmacology/therapeutic use, Polymerase Chain Reaction, Polymers/pharmacology, Polymorphism (3), population would accept the following strategy: within a continuing, Postoperative Complications|*, Postoperative/drug therapy, Postoperative|*/DT, Povidone, Practice (2), Pregnancy (2), Pregnancy Complications/*epidemiology, Prenatal Care/*utilization, Preschool, Prospective Studies, Prostitution, Protein, Protein Precursors/genetics, psoriasis, Psoriasis/*drug therapy/*immunology/pathology (2), Psoriasis/drug therapy/*genetics/immunology, Psoriasis/drug therapy/immunology, Psoriasis/metabolism/*pathology, Psoriasis/pathology, Psoriatic/*complications/*diagnosis/therapy, Psychophysics, Quality Control, Quantitative Trait Loci/*genetics, Random Allocation, Randomized Controlled Trials as Topic/*statistics & numerical data (2), rank test, RANK TRANSFORMATIONS, ras Proteins/genetics, Rats (2), Receptors (2), Recombinant Fusion Proteins/administration &, relationship between partners who have not had risky contacts in the past, Reproducibility of Results (3), Research Design, Research Design/*standards, respectively, Respiratory Tract Infections/classification/genetics/microbiology, Reverse Transcriptase Polymerase Chain Reaction, RHEUMATIC-FEVER, Rhodophyta/*chemistry, Ribavirin/*therapeutic use, Risk Factors (8), RNA (4), Rural Population, Safety, Semantics, Sensitivity and Specificity, Sequence Analysis (2), Serologic Tests, Sex Behavior, Sexual Behavior, Sexual Partners, Sexually Transmitted Diseases/*complications/diagnosis, Sexually Transmitted Diseases/*prevention & control, shows that, Signal Transduction/drug effects/genetics, Silicon Dioxide, Single Nucleotide (2), Single Nucleotide/genetics (2), Skin Neoplasms/*immunology/therapy, Skin/drug effects/immunology/pathology, Smoking, Sperm Motility/*physiology, Spermatocidal Agents, Spermatocidal Agents/adverse effects/*therapeutic use, Spermatozoa/*cytology, Sprague-Dawley, Staphylococcal Infections/classification/genetics/microbiology, Statistical (9), Statistics (3), Statistics as Topic (2), Statistics as Topic/*methods, strategy depends upon 2 factors: the reliability of the prophylaxis and, Subjective mobility, Substance-Related Disorders/genetics/metabolism, Sucrose/*pharmacology, Suppositories, Survival Rate, Syphilis/complications/diagnosis, Systemic/*blood/*genetics, t-cell, T-Lymphocyte/immunology, T-Lymphocytes (2), T-Lymphocytes/drug effects/*immunology/pathology, Tachykinins/genetics, Tanzania, the compliance of both partners with the prophylaxis methods. Probability, the less the probability of, The more frequently barrier methods are used, theory makes it possible to calculate the effectiveness of barrier methods, Therapy, therapy, there is no danger, these methods have relatively low compliance. The strategy of selecting a, Thrombosis/pathology, Thrombospondin 1/*physiology, Time Factors (2), Tourette Syndrome/genetics, Transcription, Transforming Growth Factor beta1/*metabolism/physiology, Travel desires, Treatment Outcome (4), Trichomonas Vaginitis/prevention & control, Triglycerides/blood, Tumor Necrosis Factor-alpha/*physiology, Tumor Necrosis Factor-alpha/genetics, Tumor Necrosis Factor-alpha/immunology/metabolism, under various assumptions of sexual behavior and to convert an observed, United States, Up-Regulation/drug effects/genetics, Vaccination, Viral/analysis (2), Viral/blood (2), Virus Diseases, Vomiting/*chemically induced, Vomiting|*CI, Wasp Venoms/chemistry/isolation & purification/pharmacology, Wasps/*immunology, Women's Health Services/*utilization, Young Adult (3)

Authors

M Abello (2), S Abraham, J Ahamed, F Allantaz, W Allman (2), K Anderson, J Apfelbach, M Ardura (2), M Ascano (3), L ASDERA (5), A Auerbach, N Avena, A Baday, S Bakken (2), N Baldwin, J Banchereau (5), R Barakat, R Bauer, M Becker, J Belasco, L Bennett, K von Bergmann (2), H Bewersdorff, N Bhardwaj, R Bhore (2), B Bigio (15), D Blankenship, M Blundell (2), J Breslow (5), R Bright, J Brinkley, K Burke, S Burkeholder (2), M Burns, J Büttner, P Cabassa, S Caffarri, H Carbonaro (3), I Cardinale (7), S Carini (4), L Carroll, F Casset-Semanaz, H Caussinus, S Chakraborty, F Chamian (6), D Chaussabel (2), W Chung, C Coffran (3), S Coker, B Coller, C Consortium, R Cooper, S Coquery, M Cova, W Craig, J Culiner, S Cunningham-Rundles, R Cymerman (2), R D'Agostino, M D'Onofrio, C Dadurian (4), K Damiani (2), J Daniels, H Dansky (2), A Dansky, S Dayaram, H Dbouk (2), F Dedeoglu, R Dedrick (2), D Demets, D DeMets, M Dempsey-Robertson, M Desvarieux (2), L Detwiler, M Dhodapkar (2), M Diana, K Dietz (8), P Donahue (2), A Doria, R Dorries, W Dummer (3), M Durner (2), E Dwyer, J Dyme, D Dyment, G Ebers, S Edgerton, G Ehninger, H Einsele, E Eising, A Elliman, S Esenwein, P Ettinger, J Fay (4), S Feldman, B Feldman, M Ferrari, S Flacke, K Fleischer, P Flynn, I Foeldvari, P Fonjallaz, J Friedman (2), T Fritz (2), J Fritz, J Fuentes-Duculan (2), R Fuhlbrigge, H Föllmer, D Gabriel (2), M Gail, C Gaissmaier, A Gambis (2), L Garcia-Naveda, M Garovoy (5), W Gersony, G Gholmieh (2), P Gilleaudeau (5), L Giuli, C Glaser (2), N Goddard (2), D Gordon (2), A Gottlieb (3), L Grarcia-Naveda, J Gray, D Gruber, C Grutza, H Guggenberger (2), E Guggenberger (2), M Gupta-Malhotra, H Hagler (2), A Haider (7), K Haines, C Hamer, S Hammer, U Hartmann, M Hasan, I Hasan, A Hashem (2), H Hebart, G Herr, M Herter, D Heuser (2), G Higgins (2), R Hijazi (2), J Hirsch, B Hoebel, S Hong, L Horn, A Hoshino (2), L Hudgins, M Husein, V Huser, S Husseini (2), M Ibarra, H Jacobe, G Jahn, D James, C Janczak, P Jardieu, J Jarrin, S Jim, C Johnson, D Johnson, T Johnson, D Junco, D del Junco, A Junuthula (2), E Kaizer, S Kang, C Kaplan, M Keddache, C Kelsey, A Khatcherian (4), J Kidenya, T Kikuchi (5), H Kim (2), T King (2), R Klar, T Kling, T Klingebiel, G Klintmalm, M Knut, M Koch, T Kornyat, A Kramer, J Krueger (13), G Krueger, A Kühnemann, W Küsswetter, A Lanier, R Laxer (2), E Lebovics (2), M Lebwohl, E Lee (3), H Lehmann (4), S Leibowitz, C Leonardi, M Levenstien (2), D Levine, B Levine, L Li, S Li (3), Y Li (2), M Liebling, S Lin (5), C Lindsell (2), M Ling, X Liu (3), J Loffler, M Lowes (6), D Lutjohann (2), D Lyden (2), A van den Maagdenberg, P Mackes, M Magnasco (2), M Malone, F Malvestuto (2), T Mason, J Mathieu, J Maturi (2), R McMahon, L McNamee, L Mcnamee, D Meehan (2), A Mejias (2), A Menter, L Merkov, J ter Meulen, V ter Meulen, H Mitsui, A Mohanta, S Mollah (3), L Monnet, K Moore, J Morales (3), C Muller, I Munagala, N N, F Naef, M Nahm (2), C Nasca (6), L Neff, I Novitskaya (7), R Nussbaum (3), T Nyirenda, T Nyrienda, E O'Donnell, K O'Neil, H Ochs, U Okorie, J Ono, S Opitz, R Oster (2), S Paczesny (2), G Palermo (2), A Palucka (5), K Papp (4), L Parker, T Parker, V Pascual, P Patel, C Peissert, M Peleg, M Pellegrino (3), M Pereira, M Perloe (2), A Peshansky (3), D Petitti, D Pfaff, L Pineiro, B Piqueras, F Pittiani, M Pollath, B Pollock (4), D Polsky (2), E Pope (2), M Punaro (3), E Quaia, C Quinn, E Rabinovich, C Rabinovich, S Ramagopalan, O Ramilo (2), F Ramji, T Rammsayer, H Randall, R Rehman, B Rigas (2), H Rodemann, A Rolland, M Roman, P Rosenberg, D Rubio (2), A Sadovnick, J Salit (2), R Sandmann, G Saracino, D Schaer, R Scheuermann (2), M Schiller, E Schneider (4), U Schuler, E Sehayek (5), C Seidman, S Sell, M Seybold (13), J Seydel, D Shelley, J Shen, F Shic (3), S Shiff, E Sills (3), S Sills, I Sim (4), G Simson (3), J Smith, R Soltani-Arabshahi, V Sonakya (8), T Song (13), R Spangler, M Spellman, R Steinman (4), K Stewart (2), D Stichweh, M Stoffel (2), M Suarez-Farinas (6), M Sullivan-Whalen (4), E Susser (5), M Suárez-Fariñas, J Tabbal (2), M Talaat, N Taquet, S Taquet, P Tebbey, G Terwindt, M Tonn (5), K Torok (2), S Tu (4), M Tucker (2), T University, F Vecchiato, I de Vincenzi, R Volkmann, S Wagner, P Walicke, T Walter, H Warth (2), L Welty (2), M White, P White, K Wittkowski (273), W Wuttke, R Wynden (2), H Yu (2), G Z (2), L Zaba, J Zabriskie, S Zhang, Wittkowski, NCRR

Powered by PublicationsList.org.